STAAR Surgical (NASDAQ:STAA) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc cut its stake in STAAR Surgical (NASDAQ:STAA) by 41.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 310,247 shares of the medical instruments supplier’s stock after selling 218,949 shares during the period. Ensign Peak Advisors Inc’s holdings in STAAR Surgical were worth $7,536,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical during the fourth quarter valued at $180,000. Bridgefront Capital LLC increased its holdings in shares of STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the period. Quantbot Technologies LP acquired a new position in shares of STAAR Surgical during the fourth quarter valued at $278,000. Y Intercept Hong Kong Ltd acquired a new position in shares of STAAR Surgical during the fourth quarter valued at $292,000. Finally, Counterpoint Mutual Funds LLC acquired a new position in shares of STAAR Surgical during the fourth quarter valued at $298,000. 96.70% of the stock is owned by institutional investors and hedge funds.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 8,200 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $15.08 per share, for a total transaction of $123,656.00. Following the transaction, the insider now owns 13,518,591 shares of the company’s stock, valued at $203,860,352.28. The trade was a 0.06% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased 1,482,965 shares of company stock worth $24,523,688 in the last quarter. 1.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Canaccord Genuity Group raised their price target on STAAR Surgical from $17.00 to $20.00 and gave the company a “hold” rating in a report on Thursday, May 8th. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. BTIG Research cut STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company started coverage on STAAR Surgical in a research note on Monday, April 21st. They set an “equal weight” rating and a $17.00 target price for the company. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $24.63.

STAAR Surgical Stock Down 6.3%

NASDAQ:STAA opened at $19.00 on Wednesday. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86. The firm has a market capitalization of $940.99 million, a price-to-earnings ratio of -46.34 and a beta of 0.65. The stock has a fifty day simple moving average of $17.63 and a 200 day simple moving average of $21.77.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.